http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Is Adjuvant Transarterial Chemoembolization Useful for Hepatocellular Carcinoma?
( Wong Hoi She ),( Cheung Tan To ),( Simon H. Y. Tsang ),( Wing Chiu Dai ),( Albert C. Y. Chan ),( Kenneth S. H. Chok ),( Kelvin K. C. Ng ),( Chung Mau Lo ) 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Hepatectomy is the well-established curative treatment for hepatocellular carcinoma (HCC). However, adjuvant therapy is still controversial. This study tried to look into the effect of transarterial chemoembolization (TACE) in patients receiving hepatectomy for HCC. Methods: This is a retrospective study held in a single institution using prospectively maintained database for all the patients who underwent hepatectomy for HCC between January 2000 - December 2015. The perioperative details, pathological data and outcome were studied. Patients were matched at 1:10 ratio with comparable tumor size, number, indocyanine green retention test at 15 minutes, Child’s grading and tumor staging. The Kaplan-Meier method was used for survival analysis. The log-rank test was used for survival comparison. Results: There were total 1316 patients underwent hepatectomy for HCC. 38 patients with TACE were identified, and matched with 380 patients without TACE. The patients’ characteristics including age, sex, comorbidity, Child’s grading, ICG, tumor size and numbers were the same. The median sizes of the tumor were similar (9cm in TACE vs 8cm). There was no difference in terms of intraoperative management, extent of hepatectomy and postoperative complications. There were more patients with margin involvement in TACE group (23.7% vs 7.9%, p=0.004). The staging of the disease showed no significant difference in both groups. The disease free survival was similar (12.6 (TACE) vs 10.1months, p=0.794). There was no difference in overall survival with median survival of 27.8 (TACE) vs 36.9 months (5-year overall survival of 27.9% vs 41.2%, p=0.941). Conclusions: Margin involvement was known to be adverse factor for survival. Adjuvant TACE may benefit high-risk HCC patients with margin involvement as shown to have similar survival for those patients without margin involvement.